Daniel Häußler

Daniel Häußler

Auto-generated profile, based on publicly available information

Daniel Häußler

TUM School of Medicine and Health, Institute of Experimental Oncology and Therapy Research, Technical University of Munich, 81675 Munich, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CHChris D. Hermann
Chris D. Hermann
BSBenjamin Schoeps
Benjamin Schoeps
CECelina Eckfeld
Celina Eckfeld
EMEnkhtsetseg Munkhbaatar
Enkhtsetseg Munkhbaatar
LKLukas Kniep
Lukas Kniep
AKAchim Krüger
Achim Krüger
Sex disparity in cancer is so far inadequately considered, and components of its basis are rather unknown. We reveal that male versus female pancreatic cancer (PC) patients and mice show shortened survival, more frequent liver metastasis, and elevated hepatic metastasis-promoting gene expression. Tissue inhibitor of metalloproteinases 1 (TIMP1) was the secreted factor with the strongest male-biased expression in patient-derived pancreatic tumors. Male-specific up-regulation of systemic TIMP1 was demonstrated in PC mouse models and patients. Using TIMP1-competent and TIMP1-deficient PC mouse models, we established a causal role of TIMP1 in determining shortened survival and increased liver metastasis in males. Observing TIMP1 expression as a risk parameter in males led to identification of a subpopulation exhibiting increased TIMP1 levels (T1HI males) in both primary tumors and blood. T1HI males showed increased risk for liver metastasis development not only in PC but also in colorectal cancer and melanoma. This study reveals a lifestyle-independent sex disparity in liver metastasis and may open new avenues toward precision medicine.

11 January 2023 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
CECelina Eckfeld
Celina Eckfeld
BSBenjamin Schoeps
Benjamin Schoeps
DHDaniel Häußler
Daniel Häußler
JFJulian Frädrich
Julian Frädrich
FBFelix Bayerl
Felix Bayerl
AKAchim Krüger
Achim Krüger
The emerging cytokine tissue inhibitor of metalloproteinases-1 (TIMP-1) correlates with the progression of inflammatory diseases, including cancer. However, the effects of TIMP-1 on immune cell activation and underlying molecular mechanisms are largely unknown. Unbiased ligand-receptor-capture-screening revealed TIMP-1-interaction with Amyloid Precursor Protein (APP) family members, namely APP and Amyloid Precursor-like Protein-2 (APLP2), which was confirmed by pull-down assays and confocal microscopy. We found that TIMP-1 triggered glucose uptake and proinflammatory cytokine expression in human monocytes. In cancer patients, TIMP-1 expression positively correlated with proinflammatory cytokine expression and processes associated with monocyte activation. In pancreatic cancer, TIMP-1 plasma levels correlated with the monocyte activation marker sCD163, and the combined use of both clinically accessible plasma proteins served as a powerful prognostic indicator. Mechanistically, TIMP-1 triggered monocyte activation by its C-terminal domain and via APP as demonstrated by in vitro interference, in silico docking, and the employment of recombinant TIMP-1 variants. Identification of TIMP-1 as a trigger of monocyte activation opens new therapeutic perspectives for inflammatory diseases.

6 June 2024 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
JLJordi Lambert
Jordi Lambert
SOSebnem Oc
Sebnem Oc
MWMatthew D. Worssam
Matthew D. Worssam
DHDaniel Häußler
Daniel Häußler
CSCharles U. Solomon
Charles U. Solomon
HJHelle F. Jørgensen
Helle F. Jørgensen
Aberrant vascular smooth muscle cell (VSMC) homeostasis and proliferation characterize vascular diseases causing heart attack and stroke. Here we elucidate molecular determinants governing VSMC proliferation by reconstructing gene regulatory networks from single-cell transcriptomics and epigenetic profiling. We detect widespread activation of enhancers at disease-relevant loci in proliferation-predisposed VSMCs. We compared gene regulatory network rewiring between injury-responsive and nonresponsive VSMCs, which suggested shared transcription factors but differing target loci between VSMC states. Through in silico perturbation analysis, we identified and prioritized previously unrecognized regulators of proliferation, including RUNX1 and TIMP1. Moreover, we showed that the pioneer transcription factor RUNX1 increased VSMC responsiveness and that TIMP1 feeds back to promote VSMC proliferation through CD74-mediated STAT3 signaling. Both RUNX1 and the TIMP1–CD74 axis were expressed in human VSMCs, showing low levels in normal arteries and increased expression in disease, suggesting clinical relevance and potential as vascular disease targets.

1 September 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
BSBenjamin Schoeps
Benjamin Schoeps
CECelina Eckfeld
Celina Eckfeld
LFLaura Flüter
Laura Flüter
SKSelina Keppler
Selina Keppler
RMRitu Mishra
Ritu Mishra
AKAchim Krüger
Achim Krüger
Multifunctionality of tissue inhibitor of metalloproteinases-1 (TIMP-1) comprising antiproteolytic as well as cytokinic activity has been attributed to its N-terminal and C-terminal domains, respectively. The molecular basis of the emerging proinflammatory cytokinic activity of TIMP-1 is still not completely understood. The cytokine receptor invariant chain (CD74) is involved in many inflammation-associated diseases and is highly expressed by immune cells. CD74 triggers zeta chain-associated protein kinase-70 (ZAP-70) signaling-associated activation upon interaction with its only known ligand, the macrophage migration inhibitory factor. Here, we demonstrate TIMP-1-CD74 interaction by coimmunoprecipitation and confocal microscopy in cells engineered to overexpress CD74. In silico docking in HADDOCK predicted regions of the N-terminal domain of TIMP-1 (N-TIMP-1) to interact with CD74. This was experimentally confirmed by confocal microscopy demonstrating that recombinant N-TIMP-1 lacking the entire C-terminal domain was sufficient to bind CD74. Interaction of TIMP-1 with endogenously expressed CD74 was demonstrated in the Namalwa B lymphoma cell line by dot blot binding assays as well as confocal microscopy. Functionally, we demonstrated that TIMP-1-CD74 interaction triggered intracellular ZAP-70 activation. N-TIMP-1 was sufficient to induce ZAP-70 activation and interference with the cytokine-binding site of CD74 using a synthetic peptide-abrogated TIMP-1-mediated ZAP-70 activation. Altogether, we here identified CD74 as a receptor and mediator of cytokinic TIMP-1 activity and revealed TIMP-1 as moonlighting protein harboring both cytokinic and antiproteolytic activity within its N-terminal domain. Recognition of this functional TIMP-1-CD74 interaction may shed new light on clinical attempts to therapeutically target ligand-induced CD74 activity in cancer and other inflammatory diseases.

8 May 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DHDaniel Häußler
Daniel Häußler
DMDamjan Manevski
Damjan Manevski
JFJulian Frädrich
Julian Frädrich
VBVanessa Brunner
Vanessa Brunner
OPOlga Prokopchuk
Olga Prokopchuk
AKAchim Krüger
Achim Krüger
Glycosylation emerges as a critical determinant of protein function in cancer, yet its impact on multifunctional secreted factors remains understudied. Here, we identified tissue inhibitor of metalloproteinases-1 (TIMP-1), a glycoprotein with glycosylation sites at N30 and N78 harboring both a canonical anti-proteolytic and non-canonical cytokine-like activity, as one of the most-upregulated secreted glycoproteins circulating in the blood of pancreatic cancer (PC) patients. Whereas plasma from healthy donors contained similar amounts of double- (TIMP-1glyc1/1), single-(N78 and not N30) (TIMP-1glyc0/1), and non-glycosylated (TIMP-1glyc0/0) TIMP-1, TIMP-1glyc1/1 predominated in plasma from PC patients. scRNAseq and in vitro validation linked this shift to tumor progression-associated upregulation of the oligosaccharyltransferase (OST)-complex in epithelial cells. In human PC cell lines, OST complex activity was critical for synthesis of TIMP-1glyc1/1. Importantly, tumor cell-survival and proliferation-promoting activity via CD63 were dependent on TIMP-1 glycosylation, which required N30-glycosylation. In contrast, glycosylation was not necessary for the anti-proteolytic activity of TIMP-1 towards different matrix metalloproteinases (MMPs) (collagenases MMP-1, MMP-8; gelatinases MMP-2, MMP-9; stromelysin MMP-3; Matrilysin MMP-7) but modulated the respective inhibitory efficacy. Analysis of a published glycoproteome data set, allowing assessment of individual glycosylation site occupancy in TIMP-1, revealed that N30 site occupation correlated with poor survival, while N78 site occupation showed no prognostic value, corroborating the impact of double-glycosylation of TIMP-1, as observed in patients, on tumor-promotion. The glycosylation-dependent modulation of the multifunctionality of tumor-secreted TIMP-1 thus provide a molecular basis for its long-debated cancer-promoting role. Finally, it exemplifies the impact of glycosylation macroheterogeneity on disease-relevant modulation of protein function.